Sunday, April 23, 2017 12:55:33 PM
An interesting find... This company is testing metformin delivered in the gut in a delayed fashion where it decreases systemic effects but still stimulates release of GLP-1 and related effects to lower blood sugar in type 2 diabetes. Interestingly, they presented some phase 2b study findings at the same 2013 annual meeting of European Association for Study of Diabetes (EASD) where Dr. Rojas presented the Sucanon study in Latino prediabetics. The link below outlines some further progress in phase 2b just announced in November 2016. They are a private company but have millions upon millions in venture capital signed on. Just some food for thought as we await the Sucanon trial results vs metformin, the most widely prescribed oral medication worldwide, and gold standard first line treatment per ADA.
http://elcelyx.com/wp-content/uploads/2015/06/EASD-Curtain-Raiser-FINAL.pdf
By the way, their product is most assuredly not a fraud either, and I see more than a few similarities in terms of timing and scientific potential
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM